A carregar...
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4453660/ https://ncbi.nlm.nih.gov/pubmed/25584489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.649 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|